CN1313119A - Medicinal particles for treating diabetic peripheral neuropathy - Google Patents

Medicinal particles for treating diabetic peripheral neuropathy Download PDF

Info

Publication number
CN1313119A
CN1313119A CN 01106342 CN01106342A CN1313119A CN 1313119 A CN1313119 A CN 1313119A CN 01106342 CN01106342 CN 01106342 CN 01106342 A CN01106342 A CN 01106342A CN 1313119 A CN1313119 A CN 1313119A
Authority
CN
China
Prior art keywords
hours
radix
extractum
evaporated
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 01106342
Other languages
Chinese (zh)
Other versions
CN1131050C (en
Inventor
潘英宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liaoning Aoda Pharmaceutical Co., Ltd.
Original Assignee
YINGKOU AODA PHARMACY CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by YINGKOU AODA PHARMACY CO Ltd filed Critical YINGKOU AODA PHARMACY CO Ltd
Priority to CN 01106342 priority Critical patent/CN1131050C/en
Publication of CN1313119A publication Critical patent/CN1313119A/en
Application granted granted Critical
Publication of CN1131050C publication Critical patent/CN1131050C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

A Chinese medicine in the form of particles for treating diabetic peripheral neuropathy is prepared from 9 Chinese-medicinal materials including notoginseng, corydalis tuber, red sage root, astragalus root, red peony root, etc through grinding notoginseng, alcohol reflux extraction of corydalis tuber and red sage root, decocting others, mixing then together, drying to obtain fine powder, mixing with amylin cond alcohol, granulating and drying. Its advantages include high total effective rate (96.6%), high safety, no toxic by-effect and stable and durable curative effect.

Description

The granule of treatment diabetic peripheral neuropathy
The present invention relates to a kind of granule for the treatment of diabetic peripheral neuropathy, and have the effect of invigorating blood circulation and pressing down disease.
Diabetic peripheral neuropathy is one of diabetes modal three big chronic complicating diseases, and its sickness rate can reach 90% with the prolongation of the course of disease, has become the main cause that causes the diabetics disability.This disease mainly shows as distal limbs and torso portion numb pain and sensory disturbance, its pain characteristics be the acupuncture sample or burn sample, the sample that lancinates, very person pain to attach most importance to night, has had a strong impact on patient's orthobiosis especially as amputation.Along with the carrying out of electric physiological detection technology, this sick early detective rate increases greatly in recent years.Pathogenesis about primary disease is unclear fully as yet, thinks at present mainly to cause that with diabetic supersession the opening and the perineural microangiopathies of polyhydric alcohol (mainly being sorbitol, inositol) metabolic bypass are relevant, and original rope nutrition theory of supporting one's family gets the brush-off.Cause the degeneration of neural axis to be dwindled and the Schwann cell edema and the nerve segment demyelination that occur subsequently for above-mentioned reasons, and then cause the degeneration necrosis of neurocyte.Treatment at primary disease has been considered to the clinical a great problem of present endocrine, the common drug of treatment primary disease has opioid analgesics (dolantin, lignocaine etc.) both at home and abroad, tranquilizer (dilantin etc.), antidepressant (imipramine etc.), and aldose reductase inhibitor (ARI) etc., be the product of symptomatic treatment, curative effect is undesirable takes in addition for a long time, be difficult to avoid such as toxic and side effects such as orthostatic hypotension, respiratory arrest, easy addiction, most scholars have now advocated the continuation application of these medicines of absolute limitations.Aldose reductase inhibitor (ARI) once was considered to cause the treatment effect by suppressing opening of polyhydric alcohol metabolic bypass abroad, but curative effect is excessive in yet clinical as yet by generally acknowledged, domestic also still untapped application.
The purpose of this invention is to provide a kind of new granule that utilizes the Chinese medicine diabetic peripheral neuropathy safely and effectively.
For achieving the above object, technical scheme of the present invention is: a kind of granule for the treatment of diabetic peripheral neuropathy, make by weight percentage by following raw materials according:
The Radix Astragali 10.2% Rhizoma Corydalis (vinegar system) 20.4% Radix Notoginseng 8.2%
Radix Paeoniae Rubra 12.2% Radix Salviae Miltiorrhizae 10.2% Rhizoma Chuanxiong 10.2%
Flos Carthami 10.2% Lignum Sappan 8.2% Caulis Spatholobi 10.2%
Its manufacture method is: above nine flavors, and Radix Notoginseng powder is broken into fine powder; Rhizoma Corydalis adds 70% alcohol reflux three times, adds the solvent amount and is respectively 4 times, 4 times, 2 times, and reflux extracting time is 3 hours, 2 hours, 1 hour, and merge extractive liquid, reclaims ethanol, and being evaporated to relative density is the extractum of 1.30-1.35 (60 ℃); Get Radix Salviae Miltiorrhizae and add 6 times of amounts of ethanol, refluxed 1.5 hours, filter, reclaim ethanol, being evaporated to relative density is the extractum of 1.30-1.35 (60 ℃), and medicinal residues add 6 times of amounts of 50% ethanol, refluxes 1.5 hours, filter, medicinal residues add 8 times of amounts of water, decoct 2 hours, merge second and third time filtrate, reclaim ethanol, being evaporated to relative density is the extractum of 1.30-1.35 (60 ℃); Getting the Radix Astragali, Radix Paeoniae Rubra, Rhizoma Chuanxiong, Caulis Spatholobi, Lignum Sappan, Flos Carthami decocts with water 3 times, amount of water is followed successively by 8 times, 6 times, 4 times, and decocting time was followed successively by 2 hours, 2 hours, 1 hour, filters, merging filtrate, being evaporated to relative density is the extractum of 1.30-1.35 (60 ℃), merges above-mentioned extractum and Radix Notoginseng fine powder mixing, drying under reduced pressure, powder becomes fine powder, add an amount of dextrin, use 85% alcohol granulation behind the mixing, be drying to obtain.
The present invention shows through clinical, to limbs acupuncture sample pain that diabetic peripheral neuropathy showed, burn symptoms such as sample pain or numb sample pain, total effective rate is 96.6%, obvious effective rate 50%, for the treatment of primary disease provides new active drug, and safe without toxic side effect, late result is stable.
Function of the present invention cures mainly: benefiting QI for activating blood circulation, promoting tissue regeneration by removing blood stasis, removing obstruction in the collateral to relieve pain.Medicine " the sugar end is peaceful " by name.Wherein the principal agent Radix Astragali is classical QI invigorating key medicine, sweet in the mouth, and tepor is got blood circulation depending on qi flow in the side, the meaning of the prosperous blood life of gas.Because at diabetes with the passing of time primary disease be, under the pathomechanism of blood stasis due to qi deficiency, form, so the meaning of getting its replenishing qi and promoting blood flow with this medicine is principal agent in the side.Rhizoma Corydalis is worked hard, tepor, function: promoting blood circulation to remove blood stasis, and regulating QI to relieve pain, the stagnation of QI in the energy promoting the circulation of blood, stasis in the gas is gone up the purgation pain all over the body so specially control, can be warm in nature freely in the QI and blood energy of manageing it with it, be principal agent in the side.Radix Notoginseng, sweet and slightly bitter taste, the property suffering is nontoxic, promoting blood circulation to remove blood stasis, pain relieving more can promoting tissue regeneration by removing blood stasis, is principal agent in the side.Accessory drugs is a Rhizoma Chuanxiong, and the hot temperature of property is gas medicine in the blood, blood circulation promoting and blood stasis dispelling, and removing obstruction in the collateral to relieve pain, auxiliary principal agent is strengthened the merit of promoting blood circulation, dredging meridian and relieving pain.Radix Salviae Miltiorrhizae, the bitter tepor of property is the key medicine of blood circulation promoting and blood stasis dispelling, auxiliary principal agent promoting tissue regeneration by removing blood stasis in the side, removing obstruction in the collateral to relieve pain.Radix Paeoniae Rubra is auxiliary principal agent promoting blood circulation, dredging meridian and relieving pain in the side.Flos Carthami, Lignum Sappan, Caulis Spatholobi, equal tool blood circulation promoting and blood stasis dispelling, the merit of removing obstruction in the collateral to relieve pain, with the more clinical experience approval of Lignum Sappan, Flos Carthami, three medicines are adjuvant drug altogether, play the blood circulation promoting and blood stasis dispelling tissue regeneration promoting in the side, the merit of removing obstruction in the collateral to relieve pain especially.
The clinical basic pathogenesis of diabetes shows as scorching impairment of YIN, and the cloudy QI consumed of decreasing causes deficiency of both QI and YIN.The deficiency of vital energy blood vessels stasis of blood stagnates, and venation is obstructed, and stagnation of QI and blood may bring about pain has constituted the key link of diabetic peripheral neuropathy basic pathogenesis, and result of study in recent years shows that obstruction of collaterals by blood stasis is to run through diabetes and complication important pathogenesis all the time thereof.The present invention's prescription is with benefiting QI for activating blood circulation, and promoting tissue regeneration by removing blood stasis, removing obstruction in the collateral to relieve pain are the principles of formulating prescriptions, as principal agent, gets its benefiting QI for activating blood circulation, blood circulation depending on qi flow, the meaning of promoting tissue regeneration by removing blood stasis with the Radix Astragali, Rhizoma Corydalis, Radix Notoginseng.As accessory drugs, with blood circulation promoting and blood stasis dispelling, stagnating assisted the merit of principal agent in the promoting the circulation of blood with Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra.Product with Flos Carthami, Lignum Sappan, Caulis Spatholobi promoting blood circulation, dredging meridian and relieving pain are adjuvant drug altogether, play blood circulation promoting and blood stasis dispelling tissue regeneration promoting, the merit of removing obstruction in the collateral to relieve pain in the side altogether.
Embodiment 1
A kind of granule for the treatment of diabetic peripheral neuropathy is made by weight percentage by following raw materials according: (is unit with the gram)
The Radix Astragali 312 Rhizoma Corydalis (vinegar system) 625 Radix Notoginseng 250
Radix Paeoniae Rubra 375 Radix Salviae Miltiorrhizaes 312 Rhizoma Chuanxiongs 312
Flos Carthami 312 Lignum Sappans 250 Caulis Spatholobis 312
Its manufacture method is: above nine flavors, and Radix Notoginseng powder is broken into fine powder; Rhizoma Corydalis adds 70% alcohol reflux three times, adds the solvent amount and is respectively 4 times, 4 times, 2 times, and reflux extracting time is 3 hours, 2 hours, 1 hour, and merge extractive liquid, reclaims ethanol, and being evaporated to relative density is the extractum of 1.30-1.35 (60 ℃); Get Radix Salviae Miltiorrhizae and add 6 times of amounts of ethanol, refluxed 1.5 hours, filter, reclaim ethanol, being evaporated to relative density is the extractum of 1.30-1.35 (60 ℃), and medicinal residues add 6 times of amounts of 5 0% ethanol, refluxes 1.5 hours, filter, medicinal residues add 8 times of amounts of water, decoct 2 hours, merge second and third time filtrate, reclaim ethanol, being evaporated to relative density is the extractum of 1.30-1.35 (60 ℃); Get the Radix Astragali, Radix Paeoniae Rubra, Rhizoma Chuanxiong, Caulis Spatholobi, Lignum Sappan, Flos Carthami and decoct with water 3 times, amount of water is followed successively by 8 times, 6 times, 4 times, and decocting time was followed successively by 2 hours, 2 hours, 1 hour, filter, merging filtrate, being evaporated to relative density is the extractum of 1.30-1.35 (60 ℃), merges above-mentioned extractum and Radix Notoginseng fine powder mixing, drying under reduced pressure, powder becomes fine powder, adds an amount of dextrin, uses 85% alcohol granulation behind the mixing, be drying to obtain, make 1000 grams altogether.

Claims (2)

1, a kind of granule for the treatment of diabetic peripheral neuropathy is characterized in that it is made by weight percentage by following raw materials according:
The Radix Astragali 10.2% Rhizoma Corydalis (vinegar system) 20.4% Radix Notoginseng 8.2%
Radix Paeoniae Rubra 12.2% Radix Salviae Miltiorrhizae 10.2% Rhizoma Chuanxiong 10.2%
Flos Carthami 10.2% Lignum Sappan 8.2% Caulis Spatholobi 10.2%
2, the granule of treatment diabetic peripheral neuropathy according to claim 1 is characterized in that its manufacture method is: above nine flavors, and Radix Notoginseng powder is broken into fine powder; Rhizoma Corydalis adds 70% alcohol reflux three times, adds the solvent amount and is respectively 4 times, 4 times, 2 times, and reflux extracting time is 3 hours, 2 hours, 1 hour, and merge extractive liquid, reclaims ethanol, and being evaporated to relative density is the extractum of 1.30-1.35 (60 ℃); Get Radix Salviae Miltiorrhizae and add 6 times of amounts of ethanol, refluxed 1.5 hours, filter, reclaim ethanol, being evaporated to relative density is the extractum of 1.30-1.35 (60 ℃), and medicinal residues add 6 times of amounts of 50% ethanol, refluxes 1.5 hours, filter, medicinal residues add 8 times of amounts of water, decoct 2 hours, merge second and third time filtrate, reclaim ethanol, being evaporated to relative density is the extractum of 1.30-1.35 (60 ℃); Getting the Radix Astragali, Radix Paeoniae Rubra, Rhizoma Chuanxiong, Caulis Spatholobi, Lignum Sappan, Flos Carthami decocts with water 3 times, amount of water is followed successively by 8 times, 6 times, 4 times, and decocting time was followed successively by 2 hours, 2 hours, 1 hour, filters, merging filtrate, being evaporated to relative density is the extractum of 1.30-1.35 (60 ℃), merges above-mentioned extractum and Radix Notoginseng fine powder mixing, drying under reduced pressure, powder becomes fine powder, add an amount of dextrin, use 85% alcohol granulation behind the mixing, be drying to obtain.
CN 01106342 2001-03-22 2001-03-22 Medicinal particles for treating diabetic peripheral neuropathy Expired - Lifetime CN1131050C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 01106342 CN1131050C (en) 2001-03-22 2001-03-22 Medicinal particles for treating diabetic peripheral neuropathy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 01106342 CN1131050C (en) 2001-03-22 2001-03-22 Medicinal particles for treating diabetic peripheral neuropathy

Publications (2)

Publication Number Publication Date
CN1313119A true CN1313119A (en) 2001-09-19
CN1131050C CN1131050C (en) 2003-12-17

Family

ID=4655368

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 01106342 Expired - Lifetime CN1131050C (en) 2001-03-22 2001-03-22 Medicinal particles for treating diabetic peripheral neuropathy

Country Status (1)

Country Link
CN (1) CN1131050C (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101972316A (en) * 2010-09-29 2011-02-16 辽宁奥达制药有限公司 Traditional Chinese medicinal composition, traditional Chinese medicinal preparation, preparation methods and use thereof
CN101972315A (en) * 2010-09-29 2011-02-16 辽宁奥达制药有限公司 Traditional Chinese medicinal composition and preparation method and use thereof
CN101647855B (en) * 2008-08-13 2011-11-30 贵阳中医学院 Traditional Chinese medicine preparation for treating diabetic neuropathy and preparation method thereof
CN102512518A (en) * 2012-01-05 2012-06-27 首都医科大学 Chinese medicinal extract for treating diabetic peripheral neuropathy and preparation method thereof
CN102652768A (en) * 2012-04-11 2012-09-05 南京同仁堂药业有限责任公司 Medicinal composition for relaxing tendons, activating collaterals, promoting blood circulation and removing blood stasis
CN108057077A (en) * 2018-02-09 2018-05-22 马飞 Treat Chinese medicine composition of diabete peripheral herve pathology and preparation method thereof
CN111671795A (en) * 2020-07-06 2020-09-18 西安交通大学医学院第一附属医院 Traditional Chinese medicine composition for treating diabetic peripheral neuropathy, traditional Chinese medicine preparation and application

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101647855B (en) * 2008-08-13 2011-11-30 贵阳中医学院 Traditional Chinese medicine preparation for treating diabetic neuropathy and preparation method thereof
CN101972316A (en) * 2010-09-29 2011-02-16 辽宁奥达制药有限公司 Traditional Chinese medicinal composition, traditional Chinese medicinal preparation, preparation methods and use thereof
CN101972315A (en) * 2010-09-29 2011-02-16 辽宁奥达制药有限公司 Traditional Chinese medicinal composition and preparation method and use thereof
CN101972315B (en) * 2010-09-29 2012-09-05 辽宁奥达制药有限公司 Use of traditional Chinese medicinal composition
CN101972316B (en) * 2010-09-29 2012-09-05 辽宁奥达制药有限公司 Traditional Chinese medicinal composition, use of traditional Chinese medicinal preparation
CN102512518A (en) * 2012-01-05 2012-06-27 首都医科大学 Chinese medicinal extract for treating diabetic peripheral neuropathy and preparation method thereof
CN102512518B (en) * 2012-01-05 2013-12-04 首都医科大学 Chinese medicinal extract for treating diabetic peripheral neuropathy and preparation method thereof
CN102652768A (en) * 2012-04-11 2012-09-05 南京同仁堂药业有限责任公司 Medicinal composition for relaxing tendons, activating collaterals, promoting blood circulation and removing blood stasis
CN108057077A (en) * 2018-02-09 2018-05-22 马飞 Treat Chinese medicine composition of diabete peripheral herve pathology and preparation method thereof
CN111671795A (en) * 2020-07-06 2020-09-18 西安交通大学医学院第一附属医院 Traditional Chinese medicine composition for treating diabetic peripheral neuropathy, traditional Chinese medicine preparation and application
CN111671795B (en) * 2020-07-06 2021-11-09 西安交通大学医学院第一附属医院 Traditional Chinese medicine composition for treating diabetic peripheral neuropathy, traditional Chinese medicine preparation and application

Also Published As

Publication number Publication date
CN1131050C (en) 2003-12-17

Similar Documents

Publication Publication Date Title
CN101926901B (en) Chinese medicinal oral liquid for treating chronic rhinitis and sinusitis and preparation method thereof
CN101554451A (en) Ginseng and antler muscle strengthening pills and preparation method thereof
CN101129588A (en) Instant powder for conjunctivitis
CN1131050C (en) Medicinal particles for treating diabetic peripheral neuropathy
CN100467055C (en) An external pharmaceutical for treatment of arrhythmia, coronary heart disease and angina pectoris
CN106334107A (en) Traditional Chinese medicine eye drops and preparation method thereof
CN1053110C (en) Prescription of Chinese medicine for treating cholecystitis, cholelithiasis, hepatitis and cholehepatocirrhosis
CN1060081C (en) Pure Chinese medicinal syrup preparation and its production tech.
CN103977106A (en) Traditional Chinese medicine preparation for treating nephrotic syndrome and preparation method thereof
CN1543993A (en) Rhinitis treating medicine and its preparation
CN1067817A (en) Chilblain spirit ointment, cream and preparation technology thereof
CN1059335C (en) Oral liquid for enriching blood and clearing numbness
CN1589839A (en) Stasis transforming pain relieving particle agent and its preparation method
CN101579507B (en) Medicine for treating gall stones and preparation method thereof
CN110339293A (en) A kind of arteries and veins gel resin capsule formula and preparation process
CN100998824A (en) Oral Chinese medicine for treating virus myocarditis
CN1061864C (en) Snore eliminating oral liquid
CN1280835A (en) Chinese-medicinal capsule for treating hyperlipomia
CN111773292B (en) Traditional Chinese medicine composition for treating herpes zoster as well as preparation method and application thereof
CN1352979A (en) Chinese medicine for replenishing vital energy and promoting blood circulation
CN1080571C (en) Chinese medicine for treating diseases caused by fatigue
CN101028390A (en) Medicine for treating asthma
CN101766749A (en) Chinese patent medicine for treating chronic rhinitis and nasosinusitis
CN106581553A (en) Lozenge utilizing biological extract to treat cardio-cerebrovascular diseases and preparation method thereof
CN101129571A (en) Prunellae Spica oral liquid

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: LIAONING AODA PHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME: YINGKOU AODA PHARMACEUTICAL CO.,LTD

CP03 Change of name, title or address

Address after: Lunan hi tech Industrial Development Zone, Liaoning, Yingkou

Patentee after: Liaoning Aoda Pharmaceutical Co., Ltd.

Address before: Cui Jia 68, old border area, Yingkou, Liaoning

Patentee before: Yingkou Aoda Pharmacy Co., Ltd.

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20031217